Whitehawk Therapeutics (WHWK) Other Non-Current Liabilities (2020 - 2024)
Whitehawk Therapeutics (WHWK) posted quarterly Other Non-Current Liabilities of $202000.0 for Q4 2024, down 48.6% quarter-over-quarter from $393000.0 in Q3 2024.
Whitehawk Therapeutics (WHWK) Other Non-Current Liabilities (2020 - 2024) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Other Non-Current Liabilities for 3 consecutive years, with $202000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Other Non-Current Liabilities changed N/A year-over-year to $202000.0; the TTM figure through Dec 2024 stood at $202000.0 (changed N/A YoY), while the FY2024 annual figure was $202000.0, changed N/A from the prior year.
- Other Non-Current Liabilities retreated to $202000.0 in Q4 2024 per WHWK's latest filing, from $393000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $393000.0 in Q3 2024 and bottomed at $97000.0 in Q4 2020.
- Historically, Other Non-Current Liabilities has averaged $200250.0 across 3 years, with a median of $155500.0 in 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 202,000.00 |
| Sep 30, 2024 | 393,000.00 |
| Jun 30, 2022 | 109,000.00 |
| Dec 31, 2020 | 97,000.00 |